AMGEN

UNLOCKING
THE POTENTIAL
OF BIOLOGY
FOR PATIENTS
OUR MISSION
To serve patients
Amgen is committed to unlocking the potential of biology for patients suffering from
serious illnesses by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like advanced human genetics to
unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive
for solutions that improve health outcomes and dramatically improve people’s lives. A
biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading
independent biotechnology companies, has reached millions of patients around the world
and is developing a pipeline of medicines with breakaway potential.
OUR ASPIRATION
We aspire to be the best human therapeutics
company. We will live the Amgen Values and
use science and innovation to dramatically
improve people’s lives.

AMGEN VALUES
Be science-based
Compete intensely and win
Create value for patients, staff and stockholders
Be ethical
Trust and respect each other
Ensure quality
Work in teams
Collaborate, communicate and be accountable
DAWN OF THE BIO-CENTURY
Never before have we been in a better position to understand and combat human
disease. Biotechnology has evolved rapidly in the past three decades. And yet we
remain an industry in its infancy, which means we have only begun to realize the
full potential of biotechnology and how it can benefit human health.

Many of the past century’s breakthrough innovations were in the areas of physics
and information technology. We believe we have entered an exciting new era—the
Bio-Century—where there is great potential for new discoveries as we gain a deeper
understanding of human biology and biotechnology.

Major advances in DNA sequencing and gene therapy are leading to exciting
opportunities in discovery research. We also see growing global demand for
biologic medicines on the horizon due to factors ranging from greater access
to healthcare to aging populations to new kinds of cancer treatments. And
investments are being made based on extensive knowledge of biologics
manufacturing to improve existing processes and technologies to help further
optimize the outcomes we deliver to patients.

Amgen is well positioned to break new ground in our industry—at the dawn of the
Bio-Century—and serve more patients with our therapeutics worldwide.
 Never before have we been in
a better position to understand
and combat human disease.
WHAT WE DO
PIONEERING MEDICINES
We have a presence in approximately 100 countries worldwide and have reached millions of people in the
fight against serious illnesses. We focus on six therapeutic areas: oncology/hematology, cardiovascular
disease, inflammation, bone health, nephrology and neuroscience. Our medicines typically address diseases
for which the number of effective treatment options is limited, or they are medicines that provide a viable
option to what is otherwise available.
INNOVATIVE RESEARCH
Understanding the fundamental biological mechanisms of disease is
a defining feature of Amgen’s discovery research efforts—and a major
contributor to the development of Amgen’s deep and broad pipeline of
potential new medicines. Amgen’s “biology first” approach permits its
scientists to first explore the complex molecular pathways of disease
before determining what type of medicine, or modality, is most likely
to deliver optimal efficacy and safety. As advances in human genetics
continue to shed new light on the molecular roots of disease, Amgen
subsidiary deCODE Genetics, a global leader in human genetics, is a
powerful differentiator, greatly improving how we identify and validate
human disease targets.

WORLD-CL ASS MANUFAC TURING

The treatment of millions of seriously ill patients worldwide depends
on the safe and reliable production of biologic medicines, which
are administered by injection or intravenously. A worldwide leader
in biologics manufacturing, Amgen has an outstanding track record
of reliably delivering high-quality medicines to patients who need
them. Significant skill, experience, vigilance and commitment are
critical to help ensure the quality of a biologic medicine each time a
new batch is made. At Amgen, robust quality control and a reliable
supply of medicines for patients are every bit as important as scientific
innovation.

For more information about our world-class manufacturing, visit

biotechnologybyamgen.com.
OUR HERITAGE
CULTURE OF SCIENCE AND INNOVATION
The story of Amgen began more than three decades ago with a simple idea—that emerging research in
genetics could lead to very exciting opportunities if the right scientists could be assembled and given
the appropriate resources. Amgen has since grown to be the world’s largest independent biotechnology
company, launching some of the biotechnology industry’s first blockbuster therapies, and subsequently
changing the course of medicine. As a company, we could not have accomplished what we did were it not
for our commitment to building a culture that embraces science and innovation—a culture that continues
to shape who we are today.

DELIVERING FOR PATIENTS

Amgen is counted among the early pioneers of biologic medicines. Our therapies have since reached
millions of patients worldwide. Our scientists have characterized key biologic processes that have
led to the development of innovative, first-in-class therapies. We have shaped the scientific world’s
understanding of certain disease processes. We have also engineered new types of therapeutic platforms.

AMGEN FOUNDATION
The Amgen Foundation seeks to advance excellence in science education to inspire the next generation
of innovators, and invest in strengthening communities where Amgen staff members live and work.
To date, the Foundation has donated more than $250 million in grants to local, regional and international
nonprofit organizations that impact society in inspiring and innovative ways. The Amgen Foundation
brings the excitement of discovery to the scientists of tomorrow through several signature programs,
including Amgen Scholars, Amgen Biotech Experience, and Amgen Teach. For more information, visit
www.AmgenInspires.com.
 The story of Amgen began more
than three decades ago with a simple idea—
that emerging research in genetics could
lead to very exciting opportunities if the
right scientists could be assembled and
given the appropriate resources.
KEY MILESTONES
1980 Amgen is established in
Thousand Oaks, California
1983 A
 mgen employee Fu-Kuen Lin clones
erythropoietin gene
1985 Research team at Amgen clones
granulocyte colony-stimulating
factor (G-CSF)
1989 EPOGEN (epoetin alfa) is approved
®
1991 NEUPOGEN (filgrastim) is approved
®
2001 Aranesp (darbepoetin alfa) is
®
approved
2002 Immunex, developer of Enbrel®
(etanercept), is acquired
Neulasta® (pegfilgrastim) is approved
2004 Sensipar®/Mimpara® (cinacalcet) is 2014 Amgen Singapore Manufacturing
approved Pte. Ltd. construction is completed
2006 
Vectibix® (panitumumab) is approved Asia Research and Development
Center opened in Shanghai, China
2008 Nplate® (romiplostim) is approved
BLINCYTO® (blinatumomab) is
2010 Prolia (denosumab) and XGEVA
® ® approved
(denosumab) are approved
2015 Corlanor® (ivabradine) is approved
2012 d eCODE Genetics, a global leader
in human genetics, is acquired Repatha® (evolocumab) is approved
Micromet, Inc., is acquired IMLYGIC® (talimogene laherparepvec)
is approved
2013 Amgen-Betta Pharmaceuticals joint
venture established in China
Amgen Astellas BioPharma K.K.
announces Japan alliance
Onyx Pharmaceuticals is acquired
PR ODUC TS
Aranesp® (darbepoetin alfa) NEUPOGEN® (filgrastim)
BLINCYTO® (blinatumomab) Nplate® (romiplostim)
Corlanor® (ivabradine) Prolia® (denosumab)
Enbrel® (etanercept) Repatha® (evolocumab)
EPOGEN® (epoetin alfa) Sensipar® / Mimpara®
(cinacalcet)
IMLYGIC®
(talimogene laherparepvec) Vectibix® (panitumumab)
KYPROLIS® (carfilzomib) XGEVA® (denosumab)
Neulasta® (pegfilgrastim)

For information about our pipeline and therapies, visit www.amgen.com.

 Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com

© 2016 Amgen Inc. All rights reserved. August 2016.